SCHEDULE: T. Rowe Price Discloses 8% Stake in CG Oncology

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 8.0% of CG Oncology Inc.'s common stock as of March 31, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating beneficial ownership of 6,720,389 shares of CG Oncology Inc. common stock.
• This represents 8.0% of the class of securities.
• The filing was made on May 15, 2026, with the event date requiring the filing being March 31, 2026.
• T. Rowe Price Investment Management, Inc. has sole voting power over 6,459,822 shares and sole dispositive power over 6,720,389 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest from a reputable asset manager, but it is a disclosure of existing holdings rather than new strategic information about the company's operations.

Positives

• Significant institutional ownership by T. Rowe Price Investment Management, Inc., suggesting confidence in CG Oncology's prospects.
• The ownership stake of 8.0% indicates a substantial investment.

Negatives

• The filing does not contain any negative financial or operational information about CG Oncology Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• The filing does not explicitly mention any risks related to CG Oncology Inc. The primary risk associated with this type of filing is the potential for significant changes in ownership by large institutional investors, which could impact stock price volatility.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from CG Oncology Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G from a major asset manager like T. Rowe Price can signal increased investor interest or a strategic shift in holdings within the biotechnology and oncology sectors, which are highly competitive and innovation-driven.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a positive signal, potentially leading to increased liquidity and market interest in the stock.
• Management: The significant stake may influence strategic decisions and corporate governance, as large shareholders often have a voice in company direction.

Next Steps

• Monitor future filings from T. Rowe Price Investment Management, Inc. for any changes in their stake in CG Oncology Inc.
• Observe CG Oncology Inc.'s operational and financial performance to understand the underlying reasons for institutional interest.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by T. Rowe Price Investment Management, Inc. and does not provide new operational or financial performance data for CG Oncology Inc. While the 8.0% stake indicates institutional confidence, it does not offer sufficient new information to warrant a buy or sell recommendation. A 'hold' is appropriate pending further company-specific news.

Keywords

CG Oncology, T. Rowe Price, Schedule 13G, Institutional Ownership, Beneficial Ownership, Common Stock, SEC Filing, Investment Management